Gelnique 3% is owned by Allergan.
Gelnique 3% contains Oxybutynin.
Gelnique 3% has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Gelnique 3% are:
Gelnique 3% was authorised for market use on 07 December, 2011.
Gelnique 3% is available in gel, metered;transdermal dosage forms.
The generics of Gelnique 3% are possible to be released after 25 June, 2022.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7198801||ALLERGAN||Formulations for transdermal or transmucosal application|| |
(7 months ago)
Market Authorisation Date: 07 December, 2011
Dosage: GEL, METERED;TRANSDERMAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic